Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib Combined With Anlotinib in EGFR+ NSCLC
NCT04895930Phase 2Unknown
- Sponsor
- Shanghai Chest Hospital
- Start
- Oct 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in non-small cell lung cancer (NSCLC), sponsored by Shanghai Chest Hospital. Status: unknown.
02
Drugs
furmonertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04895930.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04895930.